ANEBULO PHARMACEUTICALS, INC. Operating Cash Flow
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Operating Cash Flow of -$2.59 million for the 6-month period ending 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-02-12
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.31M.
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.27M.
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-06-30 was -$1.65M.
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-03-31 was -$1.60M.
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$6.35M.
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$8.09M.
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$9.68M.
- ANEBULO PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$5.44M.
| Period end | Net Cash Provided by (Used in) Operating Activities 2 month | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | -$1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | -$2.59M 10-Q · filed 2026-02-12 | -$4.24M derived: sum of 3 quarters · filed 2026-02-12 | -$5.84M derived: sum of 4 quarters · filed 2026-02-12 | ||
| 2025-09-30 | -$1.27M 10-Q · filed 2025-11-13 | -$2.93M derived: sum of 2 quarters · filed 2025-11-13 | -$4.53M derived: sum of 3 quarters · filed 2025-11-13 | -$5.93M derived: sum of 4 quarters · filed 2026-02-12 | ||
| 2025-06-30 | -$1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$3.25M derived: sum of 2 quarters · filed 2025-09-29 | -$4.66M derived: sum of 3 quarters · filed 2026-02-12 | -$6.35M 10-K · filed 2025-09-29 | ||
| 2025-03-31 | -$1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | -$3.01M derived: sum of 2 quarters · filed 2026-02-12 | -$4.70M 10-Q · filed 2025-05-13 | -$6.75M derived: sum of 4 quarters · filed 2026-02-12 | ||
| 2024-12-31 | -$1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | -$3.10M 10-Q · filed 2026-02-12 | -$5.15M derived: sum of 3 quarters · filed 2026-02-12 | -$6.65M derived: sum of 4 quarters · filed 2026-02-12 | ||
| 2024-09-30 | -$1.69M 10-Q · filed 2025-11-13 | -$3.74M derived: sum of 2 quarters · filed 2025-11-13 | -$5.24M derived: sum of 3 quarters · filed 2025-11-13 | -$7.05M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | -$2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$3.55M derived: sum of 2 quarters · filed 2025-09-29 | -$5.36M derived: sum of 3 quarters · filed 2025-09-29 | -$8.09M 10-K · filed 2025-09-29 | ||
| 2024-03-31 | -$1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | -$3.31M derived: sum of 2 quarters · filed 2025-05-13 | -$6.04M 10-Q · filed 2025-05-13 | -$8.89M derived: sum of 4 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | -$4.54M 10-Q · filed 2025-02-14 | -$7.39M derived: sum of 3 quarters · filed 2025-02-14 | -$9.58M derived: sum of 4 quarters · filed 2025-02-14 | ||
| 2023-09-30 | -$2.73M 10-Q · filed 2024-11-13 | -$5.58M derived: sum of 2 quarters · filed 2024-11-13 | -$7.77M derived: sum of 3 quarters · filed 2024-11-13 | -$10.38M derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | -$2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-25 | -$5.04M derived: sum of 2 quarters · filed 2024-09-25 | -$7.65M derived: sum of 3 quarters · filed 2024-09-25 | -$9.68M 10-K · filed 2024-09-25 | ||
| 2023-03-31 | -$2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | -$4.80M derived: sum of 2 quarters · filed 2024-05-15 | -$6.83M 10-Q · filed 2024-05-15 | -$8.83M derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2022-12-31 | -$2.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | -$4.64M 10-Q · filed 2024-02-13 | -$6.64M derived: sum of 3 quarters · filed 2024-02-13 | -$8.10M derived: sum of 4 quarters · filed 2024-02-13 | ||
| 2022-09-30 | -$2.03M 10-Q · filed 2023-11-14 | -$4.03M derived: sum of 2 quarters · filed 2023-11-14 | -$5.49M derived: sum of 3 quarters · filed 2023-11-14 | -$6.69M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-22 | -$3.46M derived: sum of 2 quarters · filed 2023-09-22 | -$4.66M derived: sum of 3 quarters · filed 2023-09-22 | -$5.44M 10-K · filed 2023-09-22 | ||
| 2022-03-31 | -$1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | -$2.66M derived: sum of 2 quarters · filed 2023-05-11 | -$3.44M 10-Q · filed 2023-05-11 | -$6.94M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-10 | -$1.98M 10-Q · filed 2023-02-10 | -$5.47M derived: sum of 3 quarters · filed 2023-02-10 | -$6.30M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2021-09-30 | -$777.90K 10-Q · filed 2022-11-10 | -$4.28M derived: sum of 2 quarters · filed 2022-11-10 | -$5.10M derived: sum of 3 quarters · filed 2022-11-10 | -$5.51M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | -$3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-09 | -$4.33M derived: sum of 2 quarters · filed 2022-09-09 | -$4.74M derived: sum of 3 quarters · filed 2022-09-09 | -$4.87M 10-K · filed 2022-09-09 | ||
| 2021-03-31 | -$828.90K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-11 | -$1.24M derived: sum of 2 quarters · filed 2022-05-11 | -$1.37M 10-Q · filed 2022-05-11 | -$1.77M 10-Q · filed 2021-06-21 | ||
| 2020-12-31 | -$410.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-11 | -$544.98K 10-Q · filed 2022-02-11 | ||||
| 2020-09-30 | -$134.96K 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | -$150.77K 10-K · filed 2021-09-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |